| Human immunodeficiency virus type 1 assembly, release, and maturation CS Adamson, EO Freed Advances in pharmacology 55, 347-387, 2007 | 243 | 2007 |
| Novel approaches to inhibiting HIV-1 replication CS Adamson, EO Freed Antiviral research 85 (1), 119-141, 2010 | 199 | 2010 |
| Antiviral drug discovery: preparing for the next pandemic CS Adamson, K Chibale, RJM Goss, M Jaspars, DJ Newman, ... Chemical Society Reviews 50 (6), 3647-3655, 2021 | 198 | 2021 |
| In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat) CS Adamson, SD Ablan, I Boeras, R Goila-Gaur, F Soheilian, ... Journal of virology 80 (22), 10957-10971, 2006 | 137 | 2006 |
| HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice PW Keller, CS Adamson, JB Heymann, EO Freed, AC Steven Journal of virology 85 (4), 1420-1428, 2011 | 124 | 2011 |
| The molecular basis of HIV capsid assembly—five years of progress CS Adamson, IM Jones Reviews in medical virology 14 (2), 107-121, 2004 | 98 | 2004 |
| Virus maturation as a new HIV-1 therapeutic target CS Adamson, K Salzwedel, EO Freed Expert opinion on therapeutic targets 13 (8), 895-908, 2009 | 95 | 2009 |
| Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV-1maturation inhibitor bevirimat CS Adamson, M Sakalian, K Salzwedel, EO Freed Retrovirology 7, 1-8, 2010 | 94 | 2010 |
| Far-UVC (222 nm) efficiently inactivates an airborne pathogen in a room-sized chamber E Eadie, W Hiwar, L Fletcher, E Tidswell, P O’Mahoney, M Buonanno, ... Scientific reports 12 (1), 4373, 2022 | 92 | 2022 |
| Determinants of activity of the HIV-1 maturation inhibitor PA-457 F Li, D Zoumplis, C Matallana, NR Kilgore, M Reddick, AS Yunus, ... Virology 356 (1-2), 217-224, 2006 | 79 | 2006 |
| Inhibitors of the interferon response enhance virus replication in vitro CE Stewart, RE Randall, CS Adamson PloS one 9 (11), e112014, 2014 | 75 | 2014 |
| Protease‐mediated maturation of HIV: inhibitors of protease and the maturation process CS Adamson Molecular biology international 2012 (1), 604261, 2012 | 65 | 2012 |
| Recent progress in antiretrovirals–lessons from resistance CS Adamson, EO Freed Drug discovery today 13 (9-10), 424-432, 2008 | 58 | 2008 |
| Bright and early: Inhibiting human cytomegalovirus by targeting major immediate-early gene expression or protein function CS Adamson, MM Nevels Viruses 12 (1), 110, 2020 | 57 | 2020 |
| Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457) CS Adamson, K Waki, SD Ablan, K Salzwedel, EO Freed Journal of virology 83 (10), 4884-4894, 2009 | 57 | 2009 |
| Hydrazone- and Hydrazide-Containing N-Substituted Glycines as Peptoid Surrogates for Expedited Library Synthesis: Application to the Preparation of Tsg101 … F Liu, AG Stephen, CS Adamson, K Gousset, MJ Aman, EO Freed, ... Organic letters 8 (22), 5165-5168, 2006 | 54 | 2006 |
| Molecular characterization of feline immunodeficiency virus budding BG Luttge, M Shehu-Xhilaga, DG Demirov, CS Adamson, F Soheilian, ... Journal of virology 82 (5), 2106-2119, 2008 | 51 | 2008 |
| Cloning and characterization of hIF2, a human homologue of bacterial translation initiation factor 2, and its interaction with HIV-1 matrix SA WILSON, C SIEIRO-VAZQUEZ, NJ EDWARDS, O IOURIN, ED BYLES, ... Biochemical Journal 342 (1), 97-103, 1999 | 47 | 1999 |
| Specificity and sensitivity of an RNA targeting type III CRISPR complex coupled with a NucC endonuclease effector S Grüschow, CS Adamson, MF White Nucleic acids research 49 (22), 13122-13134, 2021 | 46 | 2021 |
| Analysis of TYA protein regions necessary for formation of the Ty1 virus-like particle structure JL Brookman, AJ Stott, PJ Cheeseman, CS Adamson, D Holmes, J Cole, ... Virology 212 (1), 69-76, 1995 | 39 | 1995 |
